VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment Fully biological...
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for...